Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

Charles River Laboratories International, Inc. (NYSE: CRL) and Deciphex, a leader in AI-powered digital pathology, today announced the next phase of a strategic collaboration to focus on advancing cutting-edge image management solutions, while continuing to develop novel artificial intelligence (AI) tools for toxicologic pathology. Together, Deciphex and Charles River will deliver a fully integrated image management, distribution, and archiving workflow designed to maximize efficiency, precision, and scalability in pathology workflows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211084115/en/

“Patholytix has transformed how we manage and analyze pathology data, enabling unprecedented efficiency and collaboration across our global teams,” said Professor Julie Frearson, PhD, Corporate Senior Vice President, Chief Scientific Officer, Charles River. “This next phase of our partnership with Deciphex marks a significant milestone in advancing digital workflows for non-clinical safety assessments.”

Transforming Image Management for Pathology

This integrated solution, powered by the Patholytix platform, will provide histology laboratories and pathologists throughout the Charles River network with unparalleled capabilities to manage, share, and archive toxicologic pathology data. The system will streamline digital workflows, reduce turnaround times, and enable seamless collaboration across global teams.

“The exclusive integration of Patholytix into Charles River’s operations represents a transformative step in our mission to revolutionize digital pathology,” said Donal O’Shea, Chief Executive Officer, Deciphex. “This partnership exemplifies our commitment to delivering innovative solutions that enhance efficiency, drive collaboration, and ultimately accelerate safer drug discovery.”

Advancing AI Applications in Toxicologic Pathology

Building upon the successful 2024 launch of Foresight, the partnership will continue to enhance Deciphex’s AI-powered solutions for toxicologic pathology. These advancements will broaden tissue and lesion coverage and leverage foundational models to extend AI applications to new areas, including screening tools for acute toxicity and carcinogenicity studies. The collaboration aims to accelerate drug development and bring safer therapies to patients faster.

Efficiency Gains for Pathology Workflows

The integrated image management system, combined with AI advancements, is expected to deliver significant efficiencies, reducing the time required for non-clinical toxicology studies and enabling pathologists to focus on high-value diagnostic tasks. By combining Deciphex’s unique digital pathology solutions with Charles River’s robust toxicologic pathology network, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing decision-making in drug discovery and safety assessment.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Deciphex

Deciphex is a pioneering company at the forefront of the digital transformation of pathology. By networking with global pathologists and leveraging AI-driven solutions, Deciphex accelerates certainty in pathology reporting, ultimately enhancing patient care and advancing drug development. With a diverse and experienced team and cutting-edge platforms like Diagnexia and Patholytix, Deciphex is set to redefine the future of pathology. For more information, visit www.deciphex.com.

Contacts

Charles River Investor Contact:

Todd Spencer,

Corporate Vice President, Investor Relations

781.222.6455

todd.spencer@crl.com

Charles River Media Contact:

Amy Cianciaruso

Corporate Vice President & Chief Communications Officer

+1-781-222-6168

amy.cianciaruso@crl.com

Deciphex Media Contact

Katie Higgins

Marketing Manager

+353 1 221 0842

katie.higgins@deciphex.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.